A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects

• Published in: Pulmonary pharmacology & therapeutics Vol. 69; p. 102051
• Main Authors: Cheung, Dorothy, Fong, Alice, Ding, Han Ting, Cabanski, Christopher R., Wang, Jianshuang, Chen, Yuan, Bush, Jim, Harris, Jeffrey M., Pan, Lin
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.08.2021
• Subjects: Anti-fibrotic; First-in-human; Idiopathic pulmonary fibrosis; Multiple ascending-dose; Rabeprazole; Single ascending-dose; Anti-fibrotic; Multiple ascending-dose; Rabeprazole; Single ascending-dose; Idiopathic pulmonary fibrosis; First-in-human

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Although anti-fibrotic treatments, such as pirfenidone, are available that reduce the rate of disease progression, these medications have limitations in tolerability, and IPF patients still have poor prognoses. GDC-3280, an o...